234 related articles for article (PubMed ID: 16158824)
21. Long lasting remission by rituximab in a patient with primary cold agglutinin autoimmune haemolytic anaemia.
Glaser M; Glaser A; Skalicky M
Wien Klin Wochenschr; 2011 Nov; 123(21-22):680-3. PubMed ID: 21947363
[TBL] [Abstract][Full Text] [Related]
22. Severe refractory autoimmune hemolytic anemia with five-year complete hematologic response to third course of treatment with rituximab: a case report.
Abadie K; Hege KM
J Med Case Rep; 2014 Jun; 8():175. PubMed ID: 24889270
[TBL] [Abstract][Full Text] [Related]
23. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
Ramanathan S; Koutts J; Hertzberg MS
Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
[TBL] [Abstract][Full Text] [Related]
24. [The long-term efficacy and safety of rituximab combined with cyclophosphamide in treatment of seven patients with refractory and recurrent autoimmune hemolytic anemia].
Liu H; Xing LM; Wang HQ; Wu YH; Qu W; Liang Y; Wang GJ; Song J; Wang XM; Guan J; Li LJ; Fu R; Shao ZH
Zhonghua Nei Ke Za Zhi; 2012 Jun; 51(6):456-9. PubMed ID: 22943757
[TBL] [Abstract][Full Text] [Related]
25. Consolidation treatment with rituximab induces complete and persistent remission of mixed type Evans syndrome.
Rodella E; Pacquola E; Bianchini E; Ramazzina E; Paolini R
Blood Coagul Fibrinolysis; 2008 Jun; 19(4):315-8. PubMed ID: 18469554
[TBL] [Abstract][Full Text] [Related]
26. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
[TBL] [Abstract][Full Text] [Related]
27. Sustained remission of CIDP associated with Evans syndrome.
Knecht H; Baumberger M; Tobòn A; Steck A
Neurology; 2004 Aug; 63(4):730-2. PubMed ID: 15326255
[TBL] [Abstract][Full Text] [Related]
28. B-lymphocytes as targets for therapy in chronic cold agglutinin disease.
Berentsen S; Ulvestad E; Tjønnfjord GE
Cardiovasc Hematol Disord Drug Targets; 2007 Sep; 7(3):219-27. PubMed ID: 17896962
[TBL] [Abstract][Full Text] [Related]
29. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
Kaufman M; Limaye SA; Driscoll N; Johnson C; Caramanica A; Lebowicz Y; Patel D; Kohn N; Rai K
Leuk Lymphoma; 2009 Jun; 50(6):892-9. PubMed ID: 19391041
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment with rituximab of an infant with refractory autoimmune hemolytic anemia.
Moriya K; Matsuhashi T; Onuma M; Niizuma H; Rikiishi T; Asada H; Suzuki J; Sasahara Y; Kure S
Int J Hematol; 2013 Aug; 98(2):237-9. PubMed ID: 23702915
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.
Tanaka H; Hashimoto S; Sugita Y; Sakai S; Takeda Y; Abe D; Takagi T; Nakaseko C
Int J Hematol; 2012 Oct; 96(4):501-5. PubMed ID: 22878940
[TBL] [Abstract][Full Text] [Related]
32. Refractory cold agglutinin disease successfully treated with daratumumab. A case report and review of literature.
Mohamed A; Alkhatib M; Alshurafa A; El Omri H
Hematology; 2023 Dec; 28(1):2252651. PubMed ID: 37664905
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of IgM-monoclonal gammopathy of undetermined significance associated with cryoglobulinemia and cold agglutinin disease with immunochemotherapy with rituximab, fludarabine, and cyclophosphamide.
Bhattacharyya J; Mihara K; Takihara Y; Kimura A
Ann Hematol; 2012 May; 91(5):797-799. PubMed ID: 21901341
[No Abstract] [Full Text] [Related]
34. Current treatment strategies in autoimmune hemolytic disorders.
Barcellini W
Expert Rev Hematol; 2015 Oct; 8(5):681-91. PubMed ID: 26343892
[TBL] [Abstract][Full Text] [Related]
35. Remission of refractory lupus nephritis with a protocol including rituximab.
Fra GP; Avanzi GC; Bartoli E
Lupus; 2003; 12(10):783-7. PubMed ID: 14596429
[TBL] [Abstract][Full Text] [Related]
36. Cold agglutinin disease.
Berentsen S
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):226-231. PubMed ID: 27913484
[TBL] [Abstract][Full Text] [Related]
37. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
38. Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab.
Cheung WW; Hwang GY; Tse E; Kwong YL
Haematologica; 2006 May; 91(5 Suppl):ECR13. PubMed ID: 16709521
[TBL] [Abstract][Full Text] [Related]
39. [Delayed response to rituximab of cold agglutinin haemolytic disease].
Calvo-Villas JM; Cuesta Tovar J; Carreter de Granda E; Sicilia Guillén F
An Med Interna; 2006 May; 23(5):224-8. PubMed ID: 16817700
[TBL] [Abstract][Full Text] [Related]
40. Success of anti-CD20 monoclonal antibody treatment for severe autoimmune hemolytic anemia caused by warm-reactive immunoglobulin A, immunoglobulin G, and immunoglobulin M autoantibodies in a child: a case report.
Ajmi H; Mabrouk S; Hassayoun S; Regaieg H; Tfifha M; Jalel C; Skouri H; Zouari N; Abroug S
J Med Case Rep; 2017 Nov; 11(1):321. PubMed ID: 29132419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
